PDCD1 and acute respiratory distress syndrome: Preclinical experiments using ARDS [18] models showed a survival benefit of PD-1 pathway inhibition, suggesting that PD-1 expression on immune cells could be an outcome biomarker in patients with sepsis [19–21] and ARDS [18].